Overview

Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

Status:
Active, not recruiting

Trial end date:
2023-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this randomized clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor of clinical response in recurrent epithelial ovarian cancer (EOC), fallopian tube, or primary peritoneal cancer, regardless of platinum sensitivity. Population studied will be female participants experiencing a 1st, 2nd, or 3rd recurrence of any stage epithelial ovarian cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Cordgenics, LLC

Treatments:

Bevacizumab
Carboplatin
Cisplatin
Docetaxel
Doxorubicin
Gemcitabine
Liposomal doxorubicin
Paclitaxel
Topotecan